Fig. 2
From: Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
Clinical Response to TSHR19CAR-T Therapy. A PET-CT images of the lesions and pathological lymph nodes before (day −8) and after TSHR + CD19 CAR-T infusion (day 90). These illustrated lesions, including a target lesion at the inferior lobe of right lung (T1), a target lesion at the middle lobe of right lung (T2), a non-target pathological lymph node at the hilum of right lung metastasis (T3), a target pathological lymph node at the inferior mediastinal nodes 7 (T4), a non-target pathological lymph node at the tight supraclavicular region (T5), and a non-target lesion at the anterior lower esophagus (T6), were remarkably resolved after TSHR + CD19 CAR-T Cells infusion. All lesions and pathological lymph nodes were shrinking dramatically, achieving a partial remission and a partial metabolic response by day 90 according to RECIST 1.1 and PERCIST 1.0. B The changes in tumor volumes (mm3) of the lesions or pathological lymph nodes with CAR-T cell therapy. C The changes of the maximum standard unit value (SUVmax) of the lesions and pathological lymph nodes with CAR-T cell therapy